Press Releases

Parkinson’s Disease Therapeutics Market to exceed the US$ 5.24 Bn by 2030

Share This Article

Parkinson’s Disease Therapeutics Market – Snapshot

The global Parkinson’s disease therapeutics market is growing with high prevalence and rise in incidences of Parkinson’s disease across the developed countries. The global Parkinson’s disease therapeutics market was valued at US$ 2.18 Bn in 2016 and is projected to witness cumulative annual growth rate (CAGR) of more than 10.9% from 2017 to 2025 to exceed the US$ 5.24 Bn by 2025. The global Parkinson’s disease therapeutics market is witnessing a relatively high growth owing to rise in awareness regarding Parkinson’s disease, rapidly growing geriatric population, promising pipeline drugs, and new product launches.

Get the sample copy of report@ https://qyresearchmedical.com/sample/112009

Parkinson’s disease is a progressive neurodegenerative disorder that affects the dopamine producing nerve cells in the brain. Parkinson’s disease primarily causes tremors, muscle stiffness, improper motor movements, and gait and balance problems. Secondary symptoms of Parkinson’s disease include anxiety, depression, and dementia. The exact cause of Parkinson’s disease is not known; it predominantly affects the older people who are above 50 years of age. Men are one-and-half times more affected by the disease than women. According to Parkinson’s Foundation based in the U.S., it is estimated that worldwide around 7 to 10 million people are affected by disease and every year around 60,000 Americans are diagnosed with it. High prevalence and rise in incidence rates of Parkinson’s disease in developed countries are driving the growth of the global Parkinson’s disease therapeutics market. Also, increase in awareness about Parkinson’s disease and high clinical R&D budget by the governments and non-profit organizations are projected to fuel the growth of the Parkinson’s therapeutics market during the forecast period. The promising product pipeline represents the potential business development opportunities during the forecast period. In the U.S., there are around 10 different drugs under clinical pipeline studies in phase 3 for treating different symptoms of Parkinson’s disease. However, patent expiration of key branded drugs and side-effects associated with therapeutic drugs are anticipated to limit the growth of the Parkinson’s disease therapeutics market during the forecast period.

Till date, there is no permanent cure available for treating Parkinson’s disease. However, medications such as levodopa combination therapy, dopamine agonists, MAO-B inhibitors, COMT inhibitors, cholinesterase inhibitors, and amantadine drugs are used to treat the different symptoms associated with the disease. Levodopa combination therapy is highly recommended and widely used for treating the motor symptoms of Parkinson’s disease

View full report@ https://qyresearchmedical.com/report/parkinsons-disease-therapeutics-market-drug-class-levodopa-combination-dopamine-agonists-mao-b-inhibitors-comt-inhibitors-route-of-administration-oral-transdermal-subcutaneous-intestinal-infusion-dis-017-2030/112009

The global Parkinson’s disease therapeutics market can be divided into four segments based on drug class, route of administration, distribution channel, and geography. In terms of drug class, the global Parkinson’s disease therapeutics market can be segmented into levodopa combination therapy, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and others. The other drug class includes cholinesterase inhibitors, amantadine, antipsychotic drugs, and vassopressant drugs. Levodopa combination therapy dominated the global Parkinson’s disease therapeutics market in 2016, holding more than 32% share of the market. The segment is projected to grow at a moderate pace during the forecast period and is poised to gain market share by the end of 2025. Levodopa combination therapy is considered a highly effective treatment for controlling the motor symptoms throughout the stages of Parkinson’s disease.

In terms of route of administration, the global Parkinson’s disease therapeutics market can be classified into oral, transdermal, subcutaneous, intestinal infusion, and others. The oral route of administration accounted for the leading share of the global market. The segment is projected to continue its dominance throughout the forecast period. The recent launch of Duopa in the U.S. has contributed to significant share of the intestinal infusion segment in the global market. The other routes of administration include sublingual film and inhalation. The anticipated launch of pipeline drugs administered through inhalation and sub-lingual route is likely to gain market share by the end of 2025. Distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment dominated the global Parkinson’s disease therapeutics market in 2016 and is likely to gain market share by the end of 2025.

Geographically, the Parkinson’s disease therapeutics market can be categorized into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe accounted for the largest share of the global Parkinson’s disease therapeutics market in 2016, followed by North America with a substantial market share. High level of awareness, increase in funding for research and grants, favorable medical reimbursement policies, high prevalence of Parkinson’s disease, rapidly growing geriatric population, and promising clinical pipeline products have contributed to the key share of Europe in the Parkinson’s disease therapeutics market. Europe is a highly attractive market and is expected to expand at a significant CAGR during the forecast period. The Parkinson’s disease therapeutics market in Asia Pacific is poised to grow at a moderate growth rate. A major share of the Parkinson’s disease therapeutics market is captured by Japan and China in Asia Pacific, primarily due to the large base of elderly people affected with Parkinson’s disease in these countries.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112009/2900

The global Parkinson’s disease therapeutics market is consolidated with a few companies accounting for majority of its share. Leading players operating in the global Parkinson’s disease therapeutics market include Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., and UCB Inc., which exhibit wide geographical outreach. Manufacturers are adopting new product commercialization in the international market to tap the unmet needs of Parkinson’s disease. Other prominent players operating in the global market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.

The global Parkinson’s disease therapeutics market is segmented as follows:

Drug Class

  • Levodopa Combination
  • Dopamine Agonists
  • MAO-B Inhibitors
  • COMT Inhibitors
  • Others

Route of Administration

  • Oral
  • Transdermal
  • Subcutaneous
  • Intestinal Infusion
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America (LATAM)
  • Brazil
  • Mexico
  • Rest of LATAM
  • Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT

Chapter 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2 Assumptions and Research Methodology

Chapter 3 Executive Summary: Global Parkinson’s Disease Therapeutics Market

Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments

Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
5.5. Global Parkinson’s Disease Therapeutics Market Outlook
5.6. Global Prevalence of Parkinson’s Disease
5.7. Pipeline Analysis

Chapter 6 Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
6.3.1. Levodopa Combination
6.3.2. Dopamine Agonists
6.3.3. MAO-B Inhibitors
6.3.4. COMT Inhibitors
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class

Chapter 7 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Key Findings
7.2. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
7.2.1. Oral
7.2.2. Transdermal
7.2.3. Subcutaneous
7.2.4. Intestinal Infusion
7.2.5. Others
7.3. Market Attractiveness Analysis, by Route of Administration
7.4. Key Trends

Chapter 8 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel

Chapter 9 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017-2025
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region

Chapter 10 North America Parkinson’s Disease Therapeutics Market Analysis and Forecast

………….

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112009/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Related Articles

Back to top button